Literature DB >> 27748390

Kidney cancer: IMPRINT: no survival benefit of IMA901 in RCC.

Ellen F Carney.   

Abstract

Entities:  

Year:  2016        PMID： 27748390     DOI： 10.1038/nrneph.2016.152

Source DB:  PubMed          Journal:  Nat Rev Nephrol        ISSN： 1759-5061            Impact factor:   28.314


× No keyword cloud information.
  1 in total

1.  IMA901, a multipeptide cancer vaccine, plus sunitinib versus sunitinib alone, as first-line therapy for advanced or metastatic renal cell carcinoma (IMPRINT): a multicentre, open-label, randomised, controlled, phase 3 trial.

Authors:  Brian I Rini; Arnulf Stenzl; Romauld Zdrojowy; Mikhail Kogan; Mikhail Shkolnik; Stephane Oudard; Steffen Weikert; Sergio Bracarda; Simon J Crabb; Jens Bedke; Joerg Ludwig; Dominik Maurer; Regina Mendrzyk; Claudia Wagner; Andrea Mahr; Jens Fritsche; Toni Weinschenk; Steffen Walter; Alexandra Kirner; Harpreet Singh-Jasuja; Carsten Reinhardt; Tim Eisen
Journal:  Lancet Oncol       Date:  2016-10-03       Impact factor: 41.316
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.